ATOS241220C4000
- 0.03
- 0.000.00%
Atossa Therapeutics Newsroom
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Atossa Therapeutics Announces Five Abstracts on Z-endoxifen
Express News | Atossa Therapeutics To Present Five Abstracts For Data Regarding (Z)-Endoxifen At 2024 San Antonio Breast Cancer Symposium
Express News | Atossa Therapeutics- Got Into Open Market Sale Agreement, May Offer & Sell Shares of Our Common Stock of up to $100 Mln From Time to Time - SEC Filing
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7
Promising Developments in Atossa Therapeutics: Advancing Endoxifen Treatments
Atossa Therapeutics | 8-K: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Atossa Therapeutics | 10-Q: Q3 2024 Earnings Report
Atossa Therapeutics Reports Q3 EPS (6c), Consensus (6c)
Express News | Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Atossa Therapeutics Q3 Operating Expenses USD 6.385 Million
Press Release: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Atossa Therapeutics 3Q Loss/Shr 6c >ATOS
Press Release: Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Express News | Atossa Therapeutics Appoints Claudia Lopez, Dvm, MSC, as Vice President, Clinical Product Development
Promising Phase 2 Results and Strong Safety Profile Support Buy Recommendation for Atossa Therapeutics
Atossa Repots Topline Data From the KARISMA-Endoxifen Phase 2 Study
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6